Why is Dasatinib not reimbursed?

Dasatinib (Dasatinib) is a cancer drug that slows the growth and spread of cancer cells in the body. Dasatinib is used to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in adults and children, and is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children. Dasatinib can lower blood cells, help the body fight infection, and help blood clot.

Study shows once-daily use of dasatinib100 mg has favorable long-term risk-benefit in patients with imatinib-resistant or intolerant chronic phase myeloid leukemia (CML-CP). Molecular and cytogenetic responses at 3 and 6 months were highly predictive of long-term outcome, with BCR ABL ≤10% at 3 months being a particularly strong predictor. For most patients who respond well to dasatinib, the risk of progression to accelerated phase (AP) or blast phase (BP) is low.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications: The price of each box of 50mg*60 tablets may be around RMB 10,000. If the patient cannot be reimbursed, it may be because he does not meet the reimbursement conditions. Overseas original drugs are more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).